Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 264 results for carcinoma

  1. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

    NICE guideline
    Last updated
    14 April 2025
    View recommendations

    Sections for NG101

  2. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

    Discontinued Reference number: GID-TA10567

    Technology appraisal guidance
    Discontinued

  4. Birch bark extract for treating epidermolysis bullosa (HST28)

    Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.

    Highly specialised technologies guidance
    Published
    20 September 2023
    View recommendations

    Sections for HST28

  5. Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

    Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA424

  6. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    18 July 2018

    Sections for TA531

  7. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA212

  8. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

    Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Last updated
    1 January 2012
    View recommendations

    Sections for TA118

  9. Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (HTG385)

    Evidence-based recommendations on Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C.

    HealthTech guidance
    Last updated
    17 January 2020
    View recommendations

    Sections for HTG385

  10. Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]

    Discontinued Reference number: GID-TAG407

    Technology appraisal guidance
    Discontinued

  11. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    Discontinued Reference number: GID-TA10841

    Technology appraisal guidance
    Discontinued

  12. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    Comes from guidance Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment Number TA333

    Research recommendation
    Published
    9 June 2015

  13. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (HTG316)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.

    HealthTech guidance
    Published
    14 August 2013
    View recommendations

    Sections for HTG316

  14. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

    Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

    Technology appraisal guidance
    Published
    27 April 2016
    View recommendations

    Sections for TA389

  15. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    HealthTech guidance
    Published
    25 July 2011
    View recommendations

    Sections for HTG268